INmune Bio (INMB) Projected to Post Earnings on Monday

INmune Bio (NASDAQ:INMB) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

INmune Bio Trading Up 5.1%

Shares of INMB stock opened at $1.33 on Friday. INmune Bio has a twelve month low of $1.21 and a twelve month high of $11.64. The company’s 50-day moving average price is $1.51 and its 200-day moving average price is $1.74. The stock has a market cap of $35.35 million, a price-to-earnings ratio of -0.63 and a beta of 0.77.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $8.00.

Institutional Investors Weigh In On INmune Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in INmune Bio by 44.8% in the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock valued at $233,000 after purchasing an additional 9,236 shares during the period. Jane Street Group LLC acquired a new stake in shares of INmune Bio during the 1st quarter worth about $142,000. Rhumbline Advisers increased its position in shares of INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after purchasing an additional 2,409 shares during the last quarter. Geode Capital Management LLC raised its holdings in INmune Bio by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock valued at $901,000 after buying an additional 25,069 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in INmune Bio in the 2nd quarter valued at about $26,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.